ES2856173T3 - Uso de FK506 para el tratamiento de la hipertensión arterial pulmonar - Google Patents
Uso de FK506 para el tratamiento de la hipertensión arterial pulmonar Download PDFInfo
- Publication number
- ES2856173T3 ES2856173T3 ES12779354T ES12779354T ES2856173T3 ES 2856173 T3 ES2856173 T3 ES 2856173T3 ES 12779354 T ES12779354 T ES 12779354T ES 12779354 T ES12779354 T ES 12779354T ES 2856173 T3 ES2856173 T3 ES 2856173T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- arterial hypertension
- pulmonary arterial
- pulmonary
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2856173T3 true ES2856173T3 (es) | 2021-09-27 |
Family
ID=47108011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12779354T Active ES2856173T3 (es) | 2011-05-02 | 2012-04-30 | Uso de FK506 para el tratamiento de la hipertensión arterial pulmonar |
| ES20211109T Active ES2954905T3 (es) | 2011-05-02 | 2012-04-30 | Uso de FK506 para el tratamiento de la hipertensión arterial pulmonar |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20211109T Active ES2954905T3 (es) | 2011-05-02 | 2012-04-30 | Uso de FK506 para el tratamiento de la hipertensión arterial pulmonar |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (enExample) |
| EP (3) | EP2704711B1 (enExample) |
| JP (1) | JP6177765B2 (enExample) |
| AU (2) | AU2012250974B9 (enExample) |
| CA (1) | CA2834368C (enExample) |
| CY (1) | CY1123900T1 (enExample) |
| DK (2) | DK3821891T3 (enExample) |
| ES (2) | ES2856173T3 (enExample) |
| FI (1) | FI3821891T3 (enExample) |
| HR (1) | HRP20210245T1 (enExample) |
| HU (1) | HUE053229T2 (enExample) |
| LT (1) | LT2704711T (enExample) |
| PL (1) | PL2704711T3 (enExample) |
| PT (2) | PT3821891T (enExample) |
| RS (1) | RS61480B1 (enExample) |
| SI (1) | SI2704711T1 (enExample) |
| SM (1) | SMT202100085T1 (enExample) |
| WO (1) | WO2012151153A1 (enExample) |
| ZA (1) | ZA201307905B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2704711T3 (pl) | 2011-05-02 | 2021-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego |
| KR102569428B1 (ko) * | 2015-01-13 | 2023-08-21 | 비버스 인크. | 폐 고혈압을 위한 병용 요법 |
| EP3294294A4 (en) * | 2015-05-08 | 2019-01-02 | Vivus, Inc. | Compositions and methods for the treatment or prevention of pulmonary hypertension |
| CN108070566A (zh) * | 2015-08-05 | 2018-05-25 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| EP3624821A4 (en) | 2017-05-19 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION |
| US12440479B2 (en) | 2018-03-28 | 2025-10-14 | Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| CN101443004B (zh) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| FR2936060B1 (fr) | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| JP2012506434A (ja) * | 2008-10-22 | 2012-03-15 | サム アマー アンド カンパニー インコーポレーテッド | 肺動脈高血圧症の治療方法 |
| PL2704711T3 (pl) | 2011-05-02 | 2021-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego |
-
2012
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 SM SM20210085T patent/SMT202100085T1/it unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en not_active Ceased
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en not_active Withdrawn
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US12521379B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12521379B2 (en) | Use of FK506 for the treatment of pulmonary arterial hypertension | |
| JP2022069476A (ja) | エンパグリフロジンの治療的使用 | |
| JP2008013577A (ja) | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト | |
| US20060183674A1 (en) | Compositions and methods for treating diabetes | |
| US20050119330A1 (en) | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases | |
| US20170042926A1 (en) | Treating ocular neovascularization | |
| US20210346357A1 (en) | Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compound | |
| AU2010234360A1 (en) | Methods and compositions of PI-3 kinase inhibitors for treating fibrosis | |
| KR20220080181A (ko) | 신독소-유도된 신장 손상의 치료 및 예방 | |
| KR20050106038A (ko) | 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제 | |
| US20230310478A1 (en) | Methods and compositions for the treatment of pulmonary hypertension and cancer | |
| US20050239759A1 (en) | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor | |
| US20240262916A1 (en) | Methods and compositions for treating cardiovascular disease | |
| Kane et al. | Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors | |
| JP2025515011A (ja) | デュシェンヌ型筋ジストロフィーを治療する方法 | |
| US10987343B2 (en) | Compositions and methods for treating pulmonary diseases | |
| Fernandez et al. | Efficacy and cardiovascular safety of SGLT2 inhibitors | |
| US20250290066A1 (en) | COMPOSITIONS FOR THE SILENCING OF snoRNAS AND METHODS OF USING SAME | |
| TW202529758A (zh) | 用於治療疾病及病症之ｈｄａｃ６選擇性抑制劑 | |
| Pabelick | Caveolin-1 Scaffolding Domain Peptide Prevents Hyperoxia-Induced Airway Remodeling in a 1 Neonatal Mouse Model 2 |